DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia

Information source: Rigshospitalet, Denmark
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Heart Failure; Hyponatremia

Intervention: Fluid restriction (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Finn Gustafsson

Official(s) and/or principal investigator(s):
Finn Gustafsson, MD, PhD, DMSci, Principal Investigator, Affiliation: Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark

Overall contact:
Finn Gustafsson, MD, PhD, DMSci, Phone: 004535459743, Email: finn.gustafsson@regionh.dk


The purpose of this study is to determine the effect of fluid restriction and the neurohormonal mechanisms in the development of hyponatremia in patients with congestive heart failure and hyponatremia. The hypothesis is that strict fluid restriction leads to a larger increase in plasma sodium than standard treatment in patients with decompensated heart failure associated with hyponatremia. A secondary hypothesis is that the neurohormonal change is greater in patients treated with strict fluid restriction versus standard treatment.

Clinical Details

Official title: The Significance of the Vasopressin System of the Hemodynamics, Water Balance and Prognosis in Chronic Heart Failure

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change in plasma sodium from day 1 to day 4: - Normalization of plasma sodium or - A significant change in plasma sodium of a minimum of 5 mmol/L from baseline to day 4

Secondary outcome:

Change in plasma vasopressin and copeptin

Change in blood pressure, heart rate, weight and oedemas

Change in dyspnoea assessed by the patient

Number of days until clinical stability

The correlation between hospitalization time and plasma sodium

Correlation between fluid restriction and change in kidney function

Patient assessment of fluid restriction

Patient compliance to fluid restriction


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Age > 18 years

- Left Ventricular Ejection Fraction (LVEF) < 40

At least two of the following signs of decompensated heart failure and fluid retention:

- Weight gain > 2 kg

- Pulmonal Congestion

- Jugular vein congestion

- Peripheral oedemas

- Hepatic congestion with ascites

- Radiographic signs of fluid retention

- Increased diuretic dose


- New York Heart Association (NYHA) class III-IV

- Plasma sodium < 135 mmol/L

- Symptomatic heart failure and treatment with relevant heart failure medications

(beta-blocker, diuretic, digoxin, angiotensin-converting-enzyme inhibitor, angiotensin-II receptor antagonist, spironolactone, hydralazine and/or nitrates)for at least 1 month

- Hospitalization for decompensated heart failure within the last 48 hours

- Given informed consent

Exclusion Criteria:

- Plasma sodium ≥ 135 mmol/L before randomization

- Reduced kidney function (creatinine > 200 μmol/L)

- Severe hematologic disease

- Hypovolemic hyponatremia (volume depletion or dehydration)

- Intolerability to large or fast changes in fluid volume assessed by the investigator

- Plasma sodium < 120 mmol/L accompanied by neurologic symptoms

- Anuria

- Symptomatic systolic blood pressure (supine systolic blood pressure < 90 mmHg)

- Uncontrolled hypertension (systolic blood pressure > 180 mmHg)

- Uncontrolled diabetes diabetes mellitus

- Adrenal insufficiency

- Acute myocardial infarction, sustained ventricular tachycardia or ventricular

fibrillation within the last 30 days

- Heart surgery within the last 60 days

- Other severe heart disease: hypertrophic cardiomyopathy, severe heart valve disease,

cardiac amyloidosis, active myocarditis, pericardial exudate which is hemodynamically significant

- Left ventricular assist device (LVAD)

- Planned revascularization procedure, electrophysiologic device implantation, mechanic

left ventricular assist device, heart transplant or any other heart surgery procedures within the next 30 days

- Cerebrovascular event within the last 6 months

- Comorbidity with an expected survival < 6 months

- Other reasons for hyponatremia: Primary syndrome of inappropriate antidiuretic

hormone secretion (SIADH), primary polydipsia, head trauma, uncontrolled hypothyroidism, adrenal insufficiency or other known pharmacologically triggered hyponatremia which is reversible upon discontinuation of the drug, hyperglycemia (pseudohyponatremia), present abuse of alcohol

- Pregnancy

- Pregnant or fertile women who are not using safe contraception

- Dementia

- Unwilling or unable to give informed consent

Locations and Contacts

Finn Gustafsson, MD, PhD, DMSci, Phone: 004535459743, Email: finn.gustafsson@regionh.dk

Bispebjerg Hospital, Copenhagen 2400, Denmark; Recruiting
Olav Wendelboe Nielsen, MD, DMSc, Phone: 004535316448, Email: owen0002@bbh.regionh.dk
Olav W Nielsen, MD, DMSci, Principal Investigator

Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen 1718, Denmark; Recruiting
Finn Gustafsson, MD, PhD, DMSci, Phone: 004535459743, Email: finn.gustafsson@regionh.dk
Louise Balling, MD, Phone: 004523451679, Email: louise.balling@dadlnet.dk
Finn Gustafsson, MD, PhD, DMSci, Principal Investigator
Louise Balling, MD, Sub-Investigator

Additional Information

Starting date: November 2012
Last updated: December 10, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017